MedTrace Logo

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

NCT02985021 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-08-05

Study results available
· View outcomes & findings →

Summary

In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.

Conditions

  • Hormone-Resistant Prostate Cancer
  • Metastatic Prostate Carcinoma
  • Recurrent Prostate Carcinoma
  • Stage IV Prostate Cancer

Interventions

DRUG

Carboplatin

Chemotherapy

DRUG

Docetaxel

Chemotherapy

Sponsors & Collaborators

  • Prostate Cancer Foundation

    collaborator OTHER

  • VA Puget Sound Health Care System

    collaborator FED

  • Seattle Institute for Biomedical and Clinical Research

    lead OTHER

Principal Investigators

  • Robert B Montgomery, MD · VA Puget Sound HCS

  • Matthew Rettig, MD · VA Greater Los Angeles HCS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02985021 on ClinicalTrials.gov